Current Location:home > Detailed Browse

Article Detail

Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells

Abstracts

Background The COVID-19 cases increased very fast in the last two months. The mortality among critically ill patients, especially the elder ones, was relatively high. Considering that most of the dead patients were caused by severe inflammation response, it is very urgent to develop effective therapeutic agents and strategies for these patients. The human umbilical cord mesenchymal stem cells (hUCMSCs) have shown very good capability to modulate immune response and repair the injured tissue with good safety. Case Presentation Here, we reported the treatment process and clinical outcome of a 65-year-old female critically ill COVID-19 patient infected with 2019-nCoV (now called SARS-CoV-2). The significant clinical outcome and well tolerance was observed by the adoptive transfer of allogenic hUCMSCs. Conclusions Our results suggested that the adoptive transfer therapy of hUCMSCs might be an ideal choice to be used or combined with other immune modulating agents to treat the critically ill COVID-19 patients.
Download Comment Hits:21379 Downloads:3789
From: 高艳锋
DOI:10.12074/202002.00084
Recommended references: Bing Liang,Junhui Chen,Tao Li,Haiying Wu,Wenjie Yang,Yanjiao Li,Jianchun Li,Congtao Yu,Fangang Nie,Zhaoxia Ma,Mingxi Yang,Panrong Nie,Yanfeng Gao,Chuanyun Qian,Min Hu.(2020).Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells.[ChinaXiv:202002.00084] (Click&Copy)
Version History
[V1] 2020-02-27 19:03:42 chinaXiv:202002.00084V1 Download
Related Paper

Download

Current Browse

Change Subject Browse

Cross Subject Browse

  • - NO